# R1 Clinical-Safety Review - primary_cutaneous_anaplastic_large_cell_lymphoma (re-review)

VERDICT: APPROVE

goldens changed: no (intended: n/a - narrative KB management content, no engine/rule/calculator change)
adversarial verdict file: PRESENT (primary_cutaneous_anaplastic_large_cell_lymphoma.verdict.md) = CLEAN, no issues flagged; nothing to reconcile.

## Reconciliation with prior R1 (REVISE) - both blocking items resolved
1. DOSE LEAK ("about 30 Gy") - RESOLVED. The RT line now reads "dose and fractionation are set by
   the treating radiation oncologist per institutional protocol." No Gy/mg/mg-m2/AUC/mg-kg or numbered
   cycle/schedule anywhere in the current sidecar. DOSE-FREE now PASSES.
2. 87% ALCANZA figure - RESOLVED as grounding concern. Adversarial-verify checked it against the source
   text (devita.txt C-ALCL / CD30+ LPD passage) and found it a verbatim, correctly attributed match, not
   a fabricated/mis-remembered stat. It is a response-rate statistic (not a dose), grounded in the cited
   source, so it is acceptable in the narrative.

## Assessment against the five tests
1. SAFETY: No unsafe or absolute directive. Prognosis-excellent and spontaneous-regression framing are
   correct; observation is offered only for asymptomatic/regressing lesions. Brentuximab peripheral-
   neuropathy monitoring and nucleoside-analog infection prophylaxis are appropriately cautioned. No
   claim that would cause harm if followed. OK.
2. GROUNDING: Consistent with DeVita/NCCN standard of care - excision/local RT first-line, brentuximab
   vedotin later-line per ALCANZA with correct FDA positioning (progression after RT or >=1 systemic
   therapy), ALK-negative / EMA-negative distinction from systemic ALCL, LyP overlap and second-lymphoma
   surveillance. General-standard claims (observation option, EPOCH-type combo, pentostatin/gemcitabine,
   surveillance cadence) are each explicitly relabelled "general oncology standard, not from DeVita's
   section on this disease" - no claim is mis-attributed to DeVita. OK.
3. DOSE-FREE: PASSES. Only numeric tokens are incidence/response percentages (multifocal ~20%, ALCANZA
   87%, LyP overlap ~20%); "low-dose oral methotrexate" is a descriptor, no numeric dose. No leaked dose.
4. SCOPE: Appropriately hedged as decision-support ("may be", "reasonable option", "generally reserved
   for", referral guidance throughout). No directive overstep. OK.
5. ADVERSARIAL FLAGS: verdict = CLEAN; no flagged issue remains present. OK.

## Advisory (non-blocking)
- The peripheral-neuropathy bullet is unlabelled but is a non-numeric paraphrase of the same ALCANZA
  toxicity discussion in DeVita; safely worded, not mis-sourced. Fine to leave.
- Keep the "In the ALCANZA trial ... (87%)" attribution consistent with the source's own trial citation;
  no change needed.

Clinically safe, grounded (no DeVita mis-attribution), dose-free, and appropriately scoped. APPROVE.
